Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Editas Medicine ($EDIT) announced inking a new exclusive R&D deal with Allergan ($AGN). The deal provides Allergan with an option to license up to five of EDIT's genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in preclinical development. The collaboration also includes programs based on the CRISPR/Cas9 platform as well as CRISPR/Cpf1.

The deal offers Editas an upfront payment of $90M, milestones and sales-based royalties. Allergan will be responsible for development and commercialization of the optioned products, subject to EDIT's option to co-develop and co-promote up to two optioned products in the U.S. The company stock jumped 10 percent in the pre-market trading session.

Aethlon Medical ($AEMD) announced that it has received positive results from a single-site feasibility study to evaluate the safety of its Hemopurifier in health-comprised individuals. The study showed that the Hemopurifier was safe and well-tolerated. The final report to the FDA will include observations of viral load reduction during treatment and a quantitative post-treatment assessment of total viruses captured with the device.

The news may help the company stabilize its stock price which has lost a substantial part of its value this year so far.

 

Pfizer Inc. ($PFE) announced the launch of Zavicefta (ceftazidime/avibactam), a combination antibiotic to treat Gram-negative bacterial infections requiring hospitalization, in the UK and Germany. The drug was approved by the EMA in June, 2016. Pfizer holds global commercialization rights for the drug except in the U.S. and Canada, where the rights are held by Allergan.

Novartis ($NVS) announced receiving the FDA approval for Kisqali, designed for the treatment of HR+/HER2- metastatic breast cancer in a first-line setting.  The company’s New Drug Application, was reviewed by the FDA under its Priority Review designation which, in this case, was only 4 1/2 months.

Edge Therapeutics ($EDGE) reported randomization of the first patient in its multi-center, controlled, open-label study of intracisternal administration of EG-1962 in adults with aneurysmal subarachnoid hemorrhage. The cisternal study is expected to investigate the safety and pharmacokinetic profile of EG-1962 administered directly into the basal cisterns of the brain compared to standard of care oral nimodipine in a group of 12 patients with aSAH.

Fate Therapeutics ($FATE) reported that he U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for FATE-NK100, the Company’s first-in-class adaptive memory natural killer cell product candidate.  A first-in-human clinical trial of FATE-NK100 for advanced acute myeloid leukemia is expected to open enrollment at the Masonic Cancer Center, University of Minnesota following approval of the Center’s institutional review board.

 

MEDNAX Inc. ($MD) announced that it has acquired Midwest Perinatal Associates, P.A., a private maternal-fetal medicine physician practice based in Overland Park, Kansas., which employs eight clinicians inclusive of two full-time maternal-fetal medicine specialists, three full-time sonographers and three full-time registered nurses, as well as five non-clinical associates. This acquisition adds to the services MEDNAX provides in Kansas and Missouri which include maternal-fetal medicine and pediatric child development.

Sanofi ($SNY) announced signing a non-exclusive agreement with Voluntis, a french software company. The agreement pertains to the development of a mobile app for helping type 2 diabetics better manage their condition. The app will also enable remote monitoring by healthcare teams.  The pilot programs are expected to be launched in North America and several European cities this year. Both the parties had earlier collaborated to develope Diabeo, a software medical device that helps diabetics in France manage their basal-bolus treatment.

 

MyoKardia ($MYOK) reported that its net income was $14.3 million for the fourth quarter of 2016, compared to a net loss of $7.9 million for the fourth quarter of 2015, an increase of $22.2 million. Net loss was $13.2 million for 2016, compared to a net loss of $22.9 million for 2015, a decrease of $9.7 million. The company’s collaboration and license revenue was $28.6 million for the fourth quarter of 2016, compared to $3.6 million for the fourth quarter of 2015. Collaboration and license revenue was $39.2 million for 2016 compared to $14.2 million for 2015, an increase of $25 million.

HemaCare Corporation ($HEMA) announced that the revenue from continuing operations grew 43% to $13.8 million, while gross profit of $7.1 million increased by 62% over the prior year. Its net income from continuing operations totaled $781,000, versus a prior year loss. 

BMO Capital Markets
Downgrades
Abbott Laboratories (ABT)
Outperform -> Market Perform
$48.00
Low
BMO Capital Markets
Lowers Target
Amphastar Pharmaceuticals (AMPH)

$16.00
Low
Needham & Company LLC
Lowers Target
Amphastar Pharmaceuticals (AMPH)

$18.00
Low
Piper Jaffray Companies
Lowers Target
Amphastar Pharmaceuticals (AMPH)

$20.00
N/A
Jefferies Group LLC
Raises Target
Bio-Rad Laboratories (BIO)

$250.00 -> $300.00
Low
Cantor Fitzgerald
Reiterates
Bellicum Pharmaceuticals (BLCM)
Buy
$32.00
Low
Jefferies Group LLC
Reiterates
Bellicum Pharmaceuticals (BLCM)
Buy
$19.00
Low
Cantor Fitzgerald
Reiterates
Corbus Pharmaceuticals Holdings (CRBP)
Buy
$17.00
Low
Goldman Sachs Group
Upgrades
Quest Diagnostics (DGX)
Buy -> Conviction-Buy

Low
Cantor Fitzgerald
Reiterates
Flexion Therapeutics (FLXN)
Buy
$34.00
Low
Stifel Nicolaus
Raises Target
Hutchison China MediTech Ltd - (HCM)
Buy
$20.00 -> $22.00
Low
Piper Jaffray Companies
Reiterates
Hologic (HOLX)
Overweight

N/A
Wells Fargo & Co
Initiates
Healthequity (HQY)
Outperform

Low
Robert W. Baird
Reiterates
Innoviva (INVA)
Neutral
$11.00
Low
JPMorgan Chase & Co.
Reiterates
Novartis AG (NVS)
Neutral

Low
BMO Capital Markets
Reiterates
Oncomed Pharmaceuticals (OMED)
Buy
$18.00
N/A
Guggenheim
Initiates
Opko Health (OPK)
Buy

High
Guggenheim
Reiterates
SCYNEXIS (SCYX)
Buy
$15.00
Low
Stifel Nicolaus
Raises Target
Tabula Rasa HealthCare (TRHC)
Buy
$17.00 -> $19.00
Low

Gainers (% price change)Last TradeChangeMkt CapHarvard Bioscience, Inc.HBIO2.85+0.20 (7.55%)101.81MRadNet Inc.RDNT5.75+0.40 (7.48%)264.71MRigel PharmaceuticalsRIGL2.88+0.20 (7.46%)348.28MEndocyte, Inc.ECYT2.62+0.18 (7.38%)119.04MArray Biopharma IncARRY11.44+0.45 (4.09%)1.86BLosers (% price change)Osiris Therapeutics, Inc.OSIR3.86-1.34 (-25.77%)127.35MZIOPHARM Oncology Inc.ZIOP6.47-0.42 (-6.10%)923.49MZogenix, Inc.ZGNX10.25-0.55 (-5.09%)287.37MGen-Probe Incorporated7.57-0.40 (-5.02%)1.08BCerus CorporationCERS4.24-0.20 (-4.61%)472.71MMost Actives (dollar volume)Merck & Co., Inc.MRK64.15-0.98 (-1.50%)175.35BJohnson & JohnsonJNJ126.68+0.47 (0.37%)344.44BBristol-Myers Squibb CoBMY56.93-1.39 (-2.38%)95.77BPfizer Inc.PFE34.11+0.00 (0.00%)203.38BIncyte CorporationINCY151.03+1.79 (1.20%)30.93B